Paul Schulwitz

119391

U.S. DEPARTMENT OF COMMERCE
Patent and Trademark Office

SEARCH REQUEST FORM

Requestor's Name: Rebecca Cook 313 Serial Number: 09/047802

Date: 4/12/04 Phone: (571) 272-0561 Art Unit: 1614

Search Topic: Inv. Robert Shaw

Please write a detailed statement of search topic. Describe specifically as possible the subject matter to be searched. Define any terms that may have a special meaning. Give examples or relevent citations, authors, keywords, etc., if known. For sequences, please attach a copy of the sequence. You may include a copy of the broadest and/or most relevent claim(s).

Please search the attached compound of formula I (cl 11) to D treat cancer/neoplasm/ metastasis & the methods of claims 19, 20, 21. Search in caplus, medline, registry, appropriate DBs

Thanks

Rebecca

Rush Level Approved

TK Page

SPE, 1615

STAFF USE ONLY

Date completed: _____

Searcher: _____

Terminal time: _____

Elapsed time: _____

CPU time: _____ 4/14

Total time: _____

Number of Searches: _____

Number of Databases: _____

Search Site

_____ STIC

_____ CM-1

_____ Pre-S

Type of Search

_____ N.A. Sequence

_____ A.A. Sequence

__1__ Structure

_____ Bibliographic

Vendors

_____ IG

402.2L STN

_____ Dialog

_____ APS

_____ Geninfo

_____ SDC

_____ DARC/Questel

_____ Other

PTO-1590 (8-90)

```
=> d que l13
L1                STR
```




```
NODE ATTRIBUTES:
CONNECT IS X3  RC AT  16
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  18

STEREO ATTRIBUTES: NONE
L3             87 SEA FILE=REGISTRY SSS FUL L1
L5                STR
```




```
NODE ATTRIBUTES:
CONNECT IS E2  RC AT   5
CONNECT IS X3  RC AT  16
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  18

STEREO ATTRIBUTES: NONE
L6             2 SEA FILE=REGISTRY SUB=L3 SSS FUL L5
L7                STR
```



N @24 O @25

VAR G2=O/N/S/C
VAR G3=24/25
NODE ATTRIBUTES:
CONNECT IS X3 RC AT 16
CONNECT IS E2 RC AT 20
CONNECT IS E1 RC AT 24
CONNECT IS E1 RC AT 25
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 25

STEREO ATTRIBUTES: NONE

L8 36 SEA FILE=REGISTRY SUB=L3 SSS FUL L7
L12 12 SEA FILE=MEDLINE ABB=ON PLU=ON (L6 OR L8)
L13 0 SEA FILE=MEDLINE ABB=ON PLU=ON L12 AND (?CANCER? OR ?NEOPLAS? OR ?CARCIN? OR ?TUMOR? OR ?TUMOUR? OR ?METAST?)

```
=> d que l11
L1                STR
```



```
NODE ATTRIBUTES:
CONNECT IS X3  RC AT  16
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  18

STEREO ATTRIBUTES: NONE
L3             87 SEA FILE=REGISTRY SSS FUL L1
L5                STR
```



```
NODE ATTRIBUTES:
CONNECT IS E2  RC AT   5
CONNECT IS X3  RC AT  16
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  18

STEREO ATTRIBUTES: NONE
L6             2 SEA FILE=REGISTRY SUB=L3 SSS FUL L5
L7                STR
```



N @24 O @25

VAR G2=O/N/S/C
VAR G3=24/25
NODE ATTRIBUTES:
CONNECT IS X3 RC AT 16
CONNECT IS E2 RC AT 20
CONNECT IS E1 RC AT 24
CONNECT IS E1 RC AT 25
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 25

STEREO ATTRIBUTES: NONE
L8 36 SEA FILE=REGISTRY SUB=L3 SSS FUL L7
L10 23 SEA FILE=HCAPLUS ABB=ON PLU=ON (L6 OR L8)(L)(BAC OR DMA OR PAC OR PKT OR THU)/RL
L11 2 SEA FILE=HCAPLUS ABB=ON PLU=ON L10 AND (?CANCER? OR ?NEOPLAS? OR ?CARCIN? OR ?TUMOR? OR ?TUMOUR? OR ?METAST?)

=> d l11 ibib ab hitind hitstr 1-2

L11 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:678597 HCAPLUS
DOCUMENT NUMBER: 139:219309
TITLE: Prostacyclin derivative-containing compositions and methods of using the same for the treatment of **cancer**
INVENTOR(S): Shorr, Robert; Rothblatt, Martine
PATENT ASSIGNEE(S): United Therapeutics Corporation, USA
SOURCE: PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2003070163	A2	20030828	WO 2003-US1483	20030116

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003166728	A1	20030904	US 2002-47802	20020116

PRIORITY APPLN. INFO.: US 2002-47802 A 20020116

OTHER SOURCE(S): MARPAT 139:219309

AB The present invention is directed to a pharmaceutical compn. contg. a **cancer**-treating effective amt. of a class of prostacyclin derivs., and a pharmaceutically acceptable carrier, and to kits and methods of employing the same for the treatment of **cancer**. For example, the prostacyclin deriv. inhibited protein degrdn. and promoted apoptosis of human amelanotic melanoma cells.

IC ICM A61K

CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1, 25

ST prostacyclin protein degrdn inhibitor **cancer**

IT Prostaglandins
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(I; compns. contg. prostacyclin deriv. for **cancer** treatment)

IT Melanoma
(amelanotic; compns. contg. prostacyclin deriv. for **cancer** treatment)

IT **Antitumor** agents
Human
Neoplasm
(compns. contg. prostacyclin deriv. for **cancer** treatment)

IT Collagens, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(degrdn., inhibition of; compns. contg. prostacyclin deriv. for **cancer** treatment)

IT Drug delivery systems
(inhalants; compns. contg. prostacyclin deriv. for **cancer** treatment)

IT Drug delivery systems
(injections, i.v.; compns. contg. prostacyclin deriv. for **cancer** treatment)

IT Drug delivery systems
(injections, s.c.; compns. contg. prostacyclin deriv. for **cancer** treatment)

IT Drug delivery systems
(kits; compns. contg. prostacyclin deriv. for **cancer** treatment)

IT **Neoplasm**
(**metastasis**, inhibition of; compns. contg. prostacyclin deriv. for **cancer** treatment)

IT Drug delivery systems
(oral; compns. contg. prostacyclin deriv. for **cancer** treatment)
IT Drug delivery systems
(parenterals; compns. contg. prostacyclin deriv. for **cancer** treatment)
IT Apoptosis
(promotion of; compns. contg. prostacyclin deriv. for **cancer** treatment)
IT Extracellular matrix
(protein degrdn. in, inhibition of; compns. contg. prostacyclin deriv. for **cancer** treatment)
IT **343247-13-2P**
RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(compns. contg. prostacyclin deriv. for **cancer** treatment)
IT 823-96-1 6971-51-3, 3-Methoxybenzyl alcohol 22348-32-9 223734-62-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(compns. contg. prostacyclin deriv. for **cancer** treatment)
IT 94956-98-6P 101692-01-7P 101692-02-8P 101692-03-9P 101758-87-6P
136911-16-5P 153974-48-2P 223734-55-2P 223734-56-3P 223734-57-4P
223734-58-5P 223734-59-6P 223734-60-9P 223734-61-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(compns. contg. prostacyclin deriv. for **cancer** treatment)
IT **343247-13-2P**
RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(compns. contg. prostacyclin deriv. for **cancer** treatment)
RN 343247-13-2 HCAPLUS
CN Acetic acid, [[(1R,2R,3aS,9aS)-2,3,3a,4,9,9a-hexahydro-2-hydroxy-1-[(3R)-3-hydroxyoctyl]-1H-benz[f]inden-5-yl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L11 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:720700 HCAPLUS
DOCUMENT NUMBER: 138:19862
TITLE: The Prostacyclin Analogue Treprostinil Blocks NF.kappa.B Nuclear Translocation in Human Alveolar

Macrophages

AUTHOR(S): Raychaudhuri, Baisakhi; Malur, Anagha; Bonfield, Tracey L.; Abraham, Susamma; Schilz, Robert J.; Farver, Carol F.; Kavuru, Mani S.; Arroliga, Alejandro C.; Thomassen, Mary Jane

CORPORATE SOURCE: Department of Pulmonary and Critical Care Medicine, The Cleveland Clinic Foundation, Cleveland, OH, 44195-5038, USA

SOURCE: Journal of Biological Chemistry (2002), 277(36), 33344-33348
CODEN: JBCHA3; ISSN: 0021-9258

PUBLISHER: American Society for Biochemistry and Molecular Biology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Primary pulmonary hypertension (PPH) is characterized by increased pulmonary arterial pressure and vascular resistance. We and others have obsd. that inflammatory cytokines and infiltrates are present in the lung tissue, but the significance is uncertain. Treprostinil (TRE), a prostacyclin analog with extended half-life and chem. stability, has shown promise in the treatment of PPH. We hypothesize that TRE might exert beneficial effects in PPH by antagonizing inflammatory cytokine prodn. in the lung. Here we show that TRE dose-dependently inhibits inflammatory cytokine (**tumor** necrosis factor-.alpha., interleukin-1.beta., interleukin-6, and granulocyte macrophage colony-stimulating factor) secretion and gene expression by human alveolar macrophages. TRE blocks NF.kappa.B activation, but I.kappa.B-.alpha. phosphorylation and degrdn. are unaffected. Moreover, TRE does not affect the formation of the NF.kappa.B.cntdot.DNA complex but blocks nuclear translocation of p65. These results are the first to illustrate the anti-cytokine actions of TRE in down-regulating NF.kappa.B, not through its inhibitory component or by direct binding but by blocking nuclear translocation. These data indicate that inflammatory mechanisms may be important in the pathogenesis of PPH and cytokine antagonism by blocking NF.kappa.B may contribute to the efficacy of TRE therapy in PPH.

CC 2-9 (Mammalian Hormones)

IT Interleukin 1.beta.
Interleukin 6
Tumor necrosis factors
RL: BSU (Biological study, unclassified); BIOL (Biological study) (prostacyclin analog treprostinil blocks inflammatory cytokine secretion and NF.kappa.B nuclear translocation in human alveolar macrophages in relation to it use in primary pulmonary hypertension treatment)

IT **81846-19-7**, Treprostinil
RL: **DMA (Drug mechanism of action)**; BIOL (Biological study) (prostacyclin analog treprostinil blocks inflammatory cytokine secretion and NF.kappa.B nuclear translocation in human alveolar macrophages in relation to it use in primary pulmonary hypertension treatment)

IT **81846-19-7**, Treprostinil
RL: **DMA (Drug mechanism of action)**; BIOL (Biological study) (prostacyclin analog treprostinil blocks inflammatory cytokine secretion and NF.kappa.B nuclear translocation in human alveolar macrophages in relation to it use in primary pulmonary hypertension treatment)

RN 81846-19-7 HCAPLUS

CN Acetic acid, [[(1R,2R,3aS,9aS)-2,3,3a,4,9,9a-hexahydro-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-1H-benz[f]inden-5-yl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d que
L1 STR



NODE ATTRIBUTES:
CONNECT IS X3 RC AT 16
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE
L3 87 SEA FILE=REGISTRY SSS FUL L1
L7 STR



VAR G2=O/N/S/C
VAR G3=24/25
NODE ATTRIBUTES:
CONNECT IS X3 RC AT 16
CONNECT IS E2 RC AT 20
CONNECT IS E1 RC AT 24
CONNECT IS E1 RC AT 25
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 25

```
STEREO ATTRIBUTES: NONE
L8            36 SEA FILE=REGISTRY SUB=L3 SSS FUL L7
L17           85 SEA L8
L18            6 SEA L17 AND (CANCER OR ANTICANC? OR NEOPLAS? OR ANTINEOPLAS?
                 OR TUMOR? OR ANTITUM? OR METAST? OR CARCIN?)


=> dup rem l18
PROCESSING COMPLETED FOR L18
L19            6 DUP REM L18 (0 DUPLICATES REMOVED)
                 ANSWERS '1-2' FROM FILE BIOSIS
                 ANSWERS '3-6' FROM FILE USPATFULL

=> d l19 bib ab 1-6

L19  ANSWER 1 OF 6  BIOSIS  COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN   2003:417438  BIOSIS
DN   PREV200300417438
TI   27th Meeting of the Oesterreichische Gesellschaft fuer Lungenerkrankungen
     und Tuberkulose, Alpbach, Tyrol, Austria, May, 29-June, 1, 2003.
AU   Oesterreichische Gesellschaft fuer Lungenerkrankungen und Tuberkulose
SO   Wiener Klinische Wochenschrift, (30 Mai 2003) Vol. 115, No. 10, pp. A IV-A
     XIII. print.
     Meeting Info.: 27th Meeting of the Oesterreichische Gesellschaft fuer
     Lungenerkrankungen und Tuberkulose. Alpbach, Tyrol, Austria. May 29-June
     01, 2003. Oesterreichische Gesellschaft fuer Lungenerkrankungen und
     Tuberkulose.
     CODEN: WKWOAO. ISSN: 0043-5325.
DT   Conference; (Meeting)
     Conference; (Meeting Summary)
LA   English
ED   Entered STN: 10 Sep 2003
     Last Updated on STN: 10 Sep 2003
AB   This meeting contains abstracts of 33 papers, written in German and
     English, on a variety of topics in lung diseases in the human patient,
     including asthma bronchiale, sleep apnea syndrome, bronchial
     carcinoma, pancreatic tumor, tuberculosis, lung
     cancer, respiratory failure, actinomycosis, HIV, pulmonary
     arterial hypertension, ventilation, autofluorescence bronchoscopy,
     bronchoscopy, endoscopy simulator, smoking cessation therapy, nebulizer
     therapy, bronchoalveolar lavage, mycophenolate mofetil, treprostinil,
     high-altitude medicine, and genetics.

L19  ANSWER 2 OF 6  BIOSIS  COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN   2002:535469  BIOSIS
DN   PREV200200535469
TI   The prostacyclin analogue treprostinil blocks NFkappaB nuclear
     translocation in human alveolar macrophages.
AU   Raychaudhuri, Baisakhi; Malur, Anagha; Bonfield, Tracey L.; Abraham,
     Susamma; Schilz, Robert J.; Farver, Carol F.; Kavuru, Mani S.; Arroliga,
     Alejandro C.; Thomassen, Mary Jane [Reprint author]
CS   Dept. of Pulmonary and Critical Care Medicine, Cleveland Clinic
     Foundation, 9500 Euclid Ave., Desk A90, Cleveland, OH, 44195-5038, USA
     thomasm@ccf.org
SO   Journal of Biological Chemistry, (September 6, 2002) Vol. 277, No. 36, pp.
     33344-33348. print.
     CODEN: JBCHA3. ISSN: 0021-9258.
```

DT Article
LA English
ED Entered STN: 16 Oct 2002
Last Updated on STN: 16 Oct 2002
AB Primary pulmonary hypertension (PPH) is characterized by increased pulmonary arterial pressure and vascular resistance. We and others have observed that inflammatory cytokines and infiltrates are present in the lung tissue, but the significance is uncertain. Treprostinil (TRE), a prostacyclin analogue with extended half-life and chemical stability, has shown promise in the treatment of PPH. We hypothesize that TRE might exert beneficial effects in PPH by antagonizing inflammatory cytokine production in the lung. Here we show that TRE dose-dependently inhibits inflammatory cytokine (**tumor** necrosis factor-alpha, interleukin-1beta, interleukin-6, and granulocyte macrophage colony-stimulating factor) secretion and gene expression by human alveolar macrophages. TRE blocks NFkappaB activation, but IkappaB-alpha phosphorylation and degradation are unaffected. Moreover, TRE does not affect the formation of the NFkappaBcntdotDNA complex but blocks nuclear translocation of p65. These results are the first to illustrate the anti-cytokine actions of TRE in down-regulating NFkappaB, not through its inhibitory component or by direct binding but by blocking nuclear translocation. These data indicate that inflammatory mechanisms may be important in the pathogenesis of PPH and cytokine antagonism by blocking NFkappaB may contribute to the efficacy of TRE therapy in PPH.

L19 ANSWER 3 OF 6 USPATFULL on STN
AN 2003:307038 USPATFULL
TI Method of using prostacyclin to treat respiratory syncytial virus infections
IN Peebles, Ray Stokes, JR., Nashville, TN, UNITED STATES
Hashimoto, Koichi, Fukushima, JAPAN
Graham, Barney S., Rockville, MD, UNITED STATES
PI US 2003216474 A1 20031120
AI US 2003-389295 A1 20030314 (10)
PRAI US 2002-364395P 20020315 (60)
DT Utility
FS APPLICATION
LREP WADDEY & PATTERSON, 414 UNION STREET, SUITE 2020, BANK OF AMERICA PLAZA, NASHVILLE, TN, 37219
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 9 Drawing Page(s)
LN.CNT 1178
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention discloses methods and a kit for treating a respiratory syncytial virus infection. The method comprises providing an infection modulator, and administering a therapeutically effective amount of the infection modulator, wherein the respiratory syncytial virus infection is suppressed or precluded. The kit for suppressing a respiratory syncytial virus infection comprises an infection modulator, an applicator, and a set of instructions.

L19 ANSWER 4 OF 6 USPATFULL on STN
AN 2003:238570 USPATFULL
TI Prostacyclin derivative containing compositions and methods of using the same for the treatment of **cancer**
IN Shorr, Robert, Edison, NJ, UNITED STATES

Rothblatt, Martine, Silver Spring, MD, UNITED STATES
PI US 2003166728 A1 20030904
AI US 2002-47802 A1 20020116 (10)
DT Utility
FS APPLICATION
LREP Allen R. Kipnes, WATOV & KIPNES, P.C., P.O. BOX 247, PRINCETON JUNCTION, NJ, 08550
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 1196
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to a pharmaceutical composition containing a **cancer**-treating effective amount of a class of prostacyclin derivatives, and a pharmaceutically acceptable carrier, and to kits and methods of employing the same for the treatment of **cancer**.

L19 ANSWER 5 OF 6 USPATFULL on STN
AN 2003:159865 USPATFULL
TI Inhibitors of endothelin-1 synthesis
IN Corder, Roger, Harrow, UNITED KINGDOM
Smith, Adrian P.L., London, UNITED KINGDOM
Higenbottam, Timothy W., Sheffield, UNITED KINGDOM
Rothblatt, Martine, Silver Spring, MD, UNITED STATES
Vane, Sir John, London, UNITED KINGDOM
Lees, Delphine Dominique Marthe, London, UNITED KINGDOM
PA United Therapeutics Corporation (non-U.S. corporation)
PI US 2003109480 A1 20030612
AI US 2002-295942 A1 20021118 (10)
RLI Continuation of Ser. No. US 2000-527240, filed on 17 Mar 2000, ABANDONED
PRAI US 1999-125000P 19990318 (60)
DT Utility
FS APPLICATION
LREP FOLEY AND LARDNER, SUITE 500, 3000 K STREET NW, WASHINGTON, DC, 20007
CLMN Number of Claims: 54
ECL Exemplary Claim: 1
DRWN 19 Drawing Page(s)
LN.CNT 1357
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Sequences in human preproendothelin-1 mRNA are described against which antisense oligonucleotides can be used to inhibit the synthesis of endothelin-1. This inhibition of endothelin-1 synthesis may be used to treat diseases where excess production of endothelin-1 is an underlying cause of the symptoms.

L19 ANSWER 6 OF 6 USPATFULL on STN
AN 2003:158899 USPATFULL
TI Modified prostaglandin compounds and analogs thereof, compositions containing the same useful for the treatment of **cancer**
IN Shorr, Robert, Edison, NJ, UNITED STATES
Rothblatt, Martine, Silver Spring, MD, UNITED STATES
Bentley, Michael, Huntsvillef, AL, UNITED STATES
Zhao, Xuan, Huntsville, AL, UNITED STATES
PI US 2003108512 A1 20030612 abandoned
AI US 2001-6197 A1 20011210 (10)
DT Utility

FS APPLICATION
LREP Allen R. Kipnes, WATOV & KIPNES, P.C., P.O. BOX 247, PRINCETON JUNCTION, NJ, 08550
CLMN Number of Claims: 52
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 1415
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention is directed to a pharmaceutical composition containing a **cancer**-treating effective amount of a prostaglandin compound and analogs thereof having a metabolic rate slowing group attached thereto, and a pharmaceutically acceptable carrier, and methods of employing the same for the treatment of **cancer**.

```
=> d que l15
L1                STR
```



```
NODE ATTRIBUTES:
CONNECT IS X3  RC AT  16
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  18

STEREO ATTRIBUTES: NONE
L3             87 SEA FILE=REGISTRY SSS FUL L1
L5                STR
```



```
NODE ATTRIBUTES:
CONNECT IS E2  RC AT   5
CONNECT IS X3  RC AT  16
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  18

STEREO ATTRIBUTES: NONE
L6             2 SEA FILE=REGISTRY SUB=L3 SSS FUL L5
L7                STR
```



VAR G2=O/N/S/C
VAR G3=24/25
NODE ATTRIBUTES:
CONNECT IS X3 RC AT 16
CONNECT IS E2 RC AT 20
CONNECT IS E1 RC AT 24
CONNECT IS E1 RC AT 25
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 25

STEREO ATTRIBUTES: NONE
L8 36 SEA FILE=REGISTRY SUB=L3 SSS FUL L7
L14 108 SEA FILE=EMBASE ABB=ON PLU=ON L6 OR L8
L15 8 SEA FILE=EMBASE ABB=ON PLU=ON L14 AND (?CANCER? OR ?NEOPLAS? OR ?CARCIN? OR ?TUMOR? OR ?TUMOUR? OR ?METAST?)

=> d l15 ibib ab hitind 1-8

L15 ANSWER 1 OF 8 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN
ACCESSION NUMBER: 2003448000 EMBASE
TITLE: New drug approvals for 2002.
AUTHOR: Frantz S.; Smith A.
CORPORATE SOURCE: S. Frantz. s.frantz@nature.com
SOURCE: Nature Reviews Drug Discovery, (2003) 2/2 (95-96).
Refs: 1
ISSN: 1474-1776 CODEN: NRDDAG
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; Note
FILE SEGMENT: 006 Internal Medicine
016 Cancer
030 Pharmacology
037 Drug Literature Index
LANGUAGE: English
CT Medical Descriptors:

*drug approval
drug marketing
drug mechanism
food and drug administration
hypertension: DT, drug therapy
breast metastasis: DT, drug therapy
pulmonary hypertension: DT, drug therapy
aspergillosis: DT, drug therapy
heart disease: DT, drug therapy
narcolepsy: DT, drug therapy
cataplexy: DT, drug therapy
irritable colon: DT, drug therapy
colorectal cancer: DT, drug therapy
hepatitis B: DT, drug therapy
hypercholesterolemia: DT, drug therapy
schizophrenia: DT, drug therapy
diarrhea: DT, drug therapy
cryptosporidiosis: DT, drug therapy
giardiasis: DT, drug therapy
osteoporosis: DT, drug therapy
keratoconjunctivitis sicca: DT, drug therapy
migraine: DT, drug therapy
bacterial infection: DT, drug therapy
Alzheimer disease: DT, drug therapy
influenza: DT, drug therapy
erectile dysfunction: DT, drug therapy
osteoarthritis: DT, drug therapy
rheumatoid arthritis: DT, drug therapy
human
note
priority journal
Drug Descriptors:
*new drug: DT, drug therapy
*new drug: PD, pharmacology
olmesartan: DT, drug therapy
olmesartan: PD, pharmacology
fulvestrant: DT, drug therapy
fulvestrant: PD, pharmacology
uniprost: DT, drug therapy
uniprost: PD, pharmacology
voriconazole: DT, drug therapy
voriconazole: PD, pharmacology
dimyristoylphosphatidylcholine: DT, drug therapy
dimyristoylphosphatidylcholine: PD, pharmacology
oxybate sodium: DT, drug therapy
oxybate sodium: PD, pharmacology
tegaserod: DT, drug therapy
tegaserod: PD, pharmacology
oxaliplatin: CB, drug combination
oxaliplatin: DT, drug therapy
oxaliplatin: PD, pharmacology
fluorouracil: CB, drug combination
fluorouracil: DT, drug therapy
folinic acid: CB, drug combination
folinic acid: DT, drug therapy
adefovir dipivoxil: DT, drug therapy
adefovir dipivoxil: PD, pharmacology

eplerenone: DT, drug therapy
eplerenone: PD, pharmacology
ezetimibe: DT, drug therapy
ezetimibe: PD, pharmacology
hypocholesterolemic agent: DT, drug therapy
hypocholesterolemic agent: PD, pharmacology
aripiprazole: DT, drug therapy
aripiprazole: PD, pharmacology
nitazoxanide: DT, drug therapy
nitazoxanide: PD, pharmacology
parathyroid hormone[1-34]: DT, drug therapy
parathyroid hormone[1-34]: PD, pharmacology
cyclosporin A: DT, drug therapy
cyclosporin A: PD, pharmacology
eletriptan: DT, drug therapy
eletriptan: PD, pharmacology
ertapenem: DT, drug therapy
ertapenem: PD, pharmacology
telmisartan: CB, drug combination
telmisartan: DT, drug therapy
telmisartan: PD, pharmacology
hydrochlorothiazide: CB, drug combination
hydrochlorothiazide: DT, drug therapy
hydrochlorothiazide: PD, pharmacology
bosentan: DT, drug therapy
bosentan: PD, pharmacology
memantine: DT, drug therapy
memantine: PD, pharmacology
oseltamivir: DT, drug therapy
oseltamivir: PD, pharmacology
tadalafil: DT, drug therapy
tadalafil: PD, pharmacology
valdecoxib: DT, drug therapy
valdecoxib: PD, pharmacology
vardenafil: DT, drug therapy
vardenafil: PD, pharmacology
unindexed drug
hepsera
inspra
alinia
micardis plus
pritor plus
ebixa
axura
levitra

RN (olmesartan) 144689-63-4; (fulvestrant) 129453-61-8; (uniprost) **81846-19-7**; (voriconazole) 137234-62-9; (dimyristoylphosphatidylcholine) 13699-48-4, 18194-24-6; (oxybate sodium) 502-85-2; (tegaserod) 145158-71-0, 189188-57-6; (oxaliplatin) 61825-94-3; (fluorouracil) 51-21-8; (folinic acid) 58-05-9, 68538-85-2; (adefovir dipivoxil) 142340-99-6; (eplerenone) 107724-20-9; (ezetimibe) 163222-33-1; (aripiprazole) 129722-12-9; (nitazoxanide) 55981-09-4; (parathyroid hormone[1-34]) 12583-68-5, 52232-67-4; (cyclosporin A) 59865-13-3, 63798-73-2; (eletriptan) 143322-58-1, 177834-92-3; (ertapenem) 153773-82-1, 153832-38-3, 153832-46-3; (telmisartan) 144701-48-4; (hydrochlorothiazide) 58-93-5; (bosentan) 147536-97-8, 157212-55-0; (memantine) 19982-08-2, 41100-52-1; (oseltamivir) 196618-13-0,

204255-09-4, 204255-11-8; (tadalafil) 171596-29-5; (valdecoxib) 181695-72-7; (vardenafil) 224785-90-4, 224785-91-5, 224789-15-5

CN (1) Benicar; (2) Faslodex; (3) Remodulin; (4) Xyrem; (5) Zelnorm; (6) Eloxatin; (7) Hepsera; (8) Inspra; (9) Zetia; (10) Zetia; (11) Abilify; (12) Abilify; (13) Alinia; (15) Forteo; (16) Relpax; (17) Invanz; (18) Micardis plus; (19) Pritor plus; (20) Tracleer; (21) Ebixa; (22) Axura; (23) Tamiflu; (24) Cialis; (25) Bextra; (26) Bextra; (27) Levitra

CO (1) Sankyo; (2) Astra Zeneca; (3) United Therapeutics; (4) Orphan; (5) Novartis; (6) Sanofi Synthelabo; (7) Gilead; (8) Searle; (9) Merck (Singapore); (10) Schering Plough (Singapore); (11) Otsuka; (12) Bristol Myers Squibb; (13) Romark; (14) Lilly; (17) Merck Sharp and Dohme; (18) Boehringer Ingelheim; (19) Glaxo SmithKline; (20) Actelion; (21) Lundbeck; (22) Merz; (23) Hoffmann La Roche; (24) Lilly ICOS; (25) Pharmacia; (26) Pfizer; (27) Bayer; Allergan; Alliance

L15 ANSWER 2 OF 8 EMBASE
on STN

ACCESSION NUMBER: 2003396573 EMBASE

TITLE: [Pulmonary hypertension].
PULMONALE HYPERTONIE.

AUTHOR: Petkov V.; Doberer D.

CORPORATE SOURCE: Dr. V. Petkov, Univ. Klin. fur Innere Medizin IV, Klinische Abteilung fur Pulmologie, Wahringer Gurtel 18-20, A-1090 Wien, Austria. Ventzislav.Petkov@univie.ac.at

SOURCE: Journal fur Hypertonie, (2003) 7/3 (7-14).
Refs: 13
ISSN: 1028-2327 CODEN: JHYPFE

COUNTRY: Austria

DOCUMENT TYPE: Journal; (Short Survey)

FILE SEGMENT: 006 Internal Medicine
015 Chest Diseases, Thoracic Surgery and Tuberculosis
018 Cardiovascular Diseases and Cardiovascular Surgery
037 Drug Literature Index
038 Adverse Reactions Titles

LANGUAGE: German

SUMMARY LANGUAGE: English; German

AB Pulmonary Hypertension (PH) is a haemodynamic diagnosis caused by several underlying diseases. In the last years tremendous progress in pathophysiology, diagnostics and therapy of PH was made. These new insights led to the first international classification of pulmonary hypertension (Evian 1998) and at the end of the nineties the first controlled trials were launched. Although further subdivision of different aetiologies of PH will preceed, therapeutic approaches still follow the haemodynamic profiles of PH. In this article we will focus on the precapillary forms of PH, including the prototype primary pulmonary hypertension, which are characterized by similar therapeutic strategies.

CT Medical Descriptors:
*pulmonary hypertension: DI, diagnosis
*pulmonary hypertension: DT, drug therapy
*pulmonary hypertension: EP, epidemiology
*pulmonary hypertension: ET, etiology
*pulmonary hypertension: SI, side effect
*pulmonary hypertension: SU, surgery
world health organization
disease classification
symptomatology
hemodynamic parameters

lung capillary pressure
lung artery pressure
lung vascular resistance
risk factor
disease association
drug use
drug abuse
cigarette smoking
estrogen therapy
algorithm
diagnostic test
two dimensional echocardiography
lung ventilation perfusion ratio
lung scintiscanning
computer assisted tomography
conservative treatment
lung transplantation
anticoagulant therapy
lung embolism: CO, complication
lung embolism: DT, drug therapy
lung embolism: PC, prevention
human
short survey
Drug Descriptors:
*prostacyclin derivative: AD, drug administration
*prostacyclin derivative: DO, drug dose
*prostacyclin derivative: DT, drug therapy
*prostacyclin derivative: IH, inhalational drug administration
*prostacyclin derivative: IV, intravenous drug administration
*prostacyclin derivative: PO, oral drug administration
*prostacyclin derivative: SC, subcutaneous drug administration
*calcium channel blocking agent: AD, drug administration
*calcium channel blocking agent: DT, drug therapy
*calcium channel blocking agent: PO, oral drug administration
*endothelin receptor antagonist: AD, drug administration
*endothelin receptor antagonist: DT, drug therapy
*endothelin receptor antagonist: PO, oral drug administration
*phosphodiesterase inhibitor: AD, drug administration
*phosphodiesterase inhibitor: DT, drug therapy
*phosphodiesterase inhibitor: PO, oral drug administration
*vasodilator agent: AD, drug administration
*vasodilator agent: DT, drug therapy
*vasodilator agent: PO, oral drug administration
methamphetamine: TO, drug toxicity
cocaine: TO, drug toxicity
tryptophan: AE, adverse drug reaction
aminorex: AE, adverse drug reaction
fenfluramine: AE, adverse drug reaction
antineoplastic agent: AE, adverse drug reaction
antidepressant agent: AE, adverse drug reaction
oral contraceptive agent: AE, adverse drug reaction
oral contraceptive agent: AD, drug administration
oral contraceptive agent: PO, oral drug administration
estrogen: AE, adverse drug reaction
diltiazem: AD, drug administration
diltiazem: DT, drug therapy
diltiazem: PO, oral drug administration

nifedipine: AD, drug administration
nifedipine: DT, drug therapy
nifedipine: PO, oral drug administration
prostacyclin: AD, drug administration
prostacyclin: DT, drug therapy
prostacyclin: IV, intravenous drug administration
iloprost: AD, drug administration
iloprost: DT, drug therapy
iloprost: IH, inhalational drug administration
iloprost: IV, intravenous drug administration
uniprost: AD, drug administration
uniprost: DT, drug therapy
uniprost: SC, subcutaneous drug administration
beraprost: AD, drug administration
beraprost: DT, drug therapy
beraprost: PO, oral drug administration
bosentan: AD, drug administration
bosentan: DT, drug therapy
bosentan: PO, oral drug administration
sildenafil: AD, drug administration
sildenafil: DT, drug therapy
sildenafil: PO, oral drug administration
vasoactive intestinal polypeptide: DT, drug therapy
dihydralazine: AD, drug administration
dihydralazine: DT, drug therapy
dihydralazine: PO, oral drug administration
urapidil: AD, drug administration
urapidil: DT, drug therapy
urapidil: PO, oral drug administration
coumarin anticoagulant: AD, drug administration
coumarin anticoagulant: DT, drug therapy
coumarin anticoagulant: PO, oral drug administration
digitalis: AD, drug administration
digitalis: DT, drug therapy
digitalis: PO, oral drug administration
diuretic agent: AD, drug administration
diuretic agent: DT, drug therapy
diuretic agent: PO, oral drug administration
dipeptidyl carboxypeptidase inhibitor: DT, drug therapy
unindexed drug

RN (methamphetamine) 28297-73-6, 51-57-0, 537-46-2, 7632-10-2; (cocaine) 50-36-2, 53-21-4, 5937-29-1; (tryptophan) 6912-86-3, 73-22-3; (aminorex) 13425-22-4, 2207-50-3; (fenfluramine) 404-82-0, 458-24-2; (diltiazem) 33286-22-5, 42399-41-7; (nifedipine) 21829-25-4; (prostacyclin) 35121-78-9, 61849-14-7; (iloprost) 78919-13-8, 82889-99-4; (uniprost) **81846-19-7**; (beraprost) 88430-50-6, 88475-69-8; (bosentan) 147536-97-8, 157212-55-0; (sildenafil) 139755-83-2; (vasoactive intestinal polypeptide) 37221-79-7; (dihydralazine) 484-23-1; (urapidil) 34661-75-1; (digitalis) 8031-42-3, 8053-83-6

CN Flolan; Ilomedin; Viagra; Tracleer

L15 ANSWER 3 OF 8 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN

ACCESSION NUMBER: 2003252137 EMBASE

TITLE: [Consensus recommendations of the working group on pulmonary arterial hypertension of the Austrian Society for Lung Diseases and Tuberculosis].

KONSENSUS-EMPFEHLUNGEN DER ARBEITSGRUPPE PULMONALARTERIELLE HYPERTENSION DER OSTERREICHISCHEN GESELLSCHAFT FUR LUNGENERKRANKUNGEN UND TUBERKULOSE.

AUTHOR: Ziesche R.
CORPORATE SOURCE: Dr. R. Ziesche, Klinische Abteilung fur Pulmologie, Univ. Klin. fur Innere Medizin IV, Wahringer Gurtel 18-20, A-1090 Wien, Austria. rolf.ziesche@akh-wien.ac.at
SOURCE: Wiener Klinische Wochenschrift, (30 May 2003) 115/10 (351-365).
Refs: 54
ISSN: 0043-5325 CODEN: WKWOAO
COUNTRY: Austria
DOCUMENT TYPE: Journal; Conference Article
FILE SEGMENT: 015 Chest Diseases, Thoracic Surgery and Tuberculosis
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: German
CT Medical Descriptors:
*pulmonary hypertension: DI, diagnosis
*pulmonary hypertension: DT, drug therapy
*pulmonary hypertension: SI, side effect
*pulmonary hypertension: SU, surgery
Austria
medical society
lung disease
lung tuberculosis
disease classification
risk factor
treatment indication
liver toxicity: SI, side effect
human
conference paper
Drug Descriptors:
antidepressant agent: AE, adverse drug reaction
oral contraceptive agent: AE, adverse drug reaction
antineoplastic agent: AE, adverse drug reaction
cocaine
amphetamine
aminorex: AE, adverse drug reaction
fenfluramine: AE, adverse drug reaction
phentermine: AE, adverse drug reaction
tryptophan: AE, adverse drug reaction
diltiazem: DT, drug therapy
diltiazem: PO, oral drug administration
nifedipine: DT, drug therapy
nifedipine: PO, oral drug administration
prostacyclin: DT, drug therapy
prostacyclin: IV, intravenous drug administration
iloprost: DT, drug therapy
iloprost: IH, inhalational drug administration
iloprost: IV, intravenous drug administration
uniprost: DT, drug therapy
uniprost: SC, subcutaneous drug administration
beraprost: DT, drug therapy
beraprost: PO, oral drug administration
bosentan: AE, adverse drug reaction
bosentan: DT, drug therapy

bosentan: PO, oral drug administration
sildenafil: DT, drug therapy
sildenafil: PO, oral drug administration
vasoactive intestinal polypeptide: DT, drug therapy
vasoactive intestinal polypeptide: IH, inhalational drug administration
dihydralazine: DT, drug therapy
dihydralazine: PO, oral drug administration
urapidil: DT, drug therapy
urapidil: PO, oral drug administration

RN (cocaine) 50-36-2, 53-21-4, 5937-29-1; (amphetamine) 1200-47-1, 139-10-6, 156-34-3, 2706-50-5, 300-62-9, 51-62-7, 60-13-9, 60-15-1; (aminorex) 13425-22-4, 2207-50-3; (fenfluramine) 404-82-0, 458-24-2; (phentermine) 1197-21-3, 122-09-8; (tryptophan) 6912-86-3, 73-22-3; (diltiazem) 33286-22-5, 42399-41-7; (nifedipine) 21829-25-4; (prostacyclin) 35121-78-9, 61849-14-7; (iloprost) 78919-13-8, 82889-99-4; (uniprost) **81846-19-7**; (beraprost) 88430-50-6, 88475-69-8; (bosentan) 147536-97-8, 157212-55-0; (sildenafil) 139755-83-2; (vasoactive intestinal polypeptide) 37221-79-7; (dihydralazine) 484-23-1; (urapidil) 34661-75-1

CN Remodulin; Flolan; Tracleer

L15 ANSWER 4 OF 8 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN

ACCESSION NUMBER: 2003250118 EMBASE
TITLE: Recap of FDA product approvals - 2002.
SOURCE: American Journal of Health-System Pharmacy, (15 Feb 2003) 60/4 (310+312).
ISSN: 1079-2082 CODEN: AHSPEK
COUNTRY: United States
DOCUMENT TYPE: Journal; Note
FILE SEGMENT: 017 Public Health, Social Medicine and Epidemiology
037 Drug Literature Index
039 Pharmacy
LANGUAGE: English

CT Medical Descriptors:
*drug approval
food and drug administration
rheumatoid arthritis
attention deficit disorder
irritable colon
licensing
drug indication
malignant neoplastic disease
human
note
priority journal
Drug Descriptors:
*new drug
vaccine
orphan drug
adalimumab
ibritumomab tiuxetan
fulvestrant
oxaliplatin
recombinant granulocyte colony stimulating factor
rasburicase
tegaserod
diphtheria pertussis tetanus vaccine

oxybate sodium
nitazoxanide
uniprost
extraneal
strattera
elitek
daptacel
pediarix
alinia
orfadin
humira

RN (adalimumab) 331731-18-1; (ibritumomab tiuxetan) 206181-63-7; (fulvestrant) 129453-61-8; (oxaliplatin) 61825-94-3; (recombinant granulocyte colony stimulating factor) 121181-53-1; (rasburicase) 352311-12-7; (tegaserod) 145158-71-0, 189188-57-6; (oxybate sodium) 502-85-2; (nitazoxanide) 55981-09-4; (uniprost) **81846-19-7**

CN (1) Strattera; (2) Zevalin; (3) Faslodex; (4) Eloxatin; (5) Neulasta; (6) Elitek; (7) Zelnorm; (8) Daptacel; (9) Pediarix; (10) Xyrem; (11) Alinia; (12) Orfadin; (13) Remodulin; (14) Extraneal; Humira

CO (1) Lilly; (2) Idec; (3) Astra Zeneca; (5) Amgen; (6) Sanofi Synthelabo; (7) Novartis; (8) Aventis Pasteur; (9) Glaxo SmithKline; (10) Orphan; (11) Romark; (12) Swedish Orphan; (13) United Therapeutics; (14) Baxter

L15 ANSWER 5 OF 8 EMBASE
on STN

ACCESSION NUMBER: 2003080265 EMBASE
TITLE: Chronic obstructive pulmonary disease, pollution, pulmonary vascular disease, transplantation, pleural disease, and lung **cancer** in AJRCCM 2002.
AUTHOR: Tobin M.J.
CORPORATE SOURCE: Dr. M.J. Tobin, Div. of Pulmon./Critical Care Med., Hines Veterans Affairs Hospital, Route 111N, Hines, IL 60141, United States. mtobin2@lumc.edu
SOURCE: American Journal of Respiratory and Critical Care Medicine, (1 Feb 2003) 167/3 (356-370).
Refs: 98
ISSN: 1073-449X CODEN: AJCMED
COUNTRY: United States
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 015 Chest Diseases, Thoracic Surgery and Tuberculosis
016 Cancer
017 Public Health, Social Medicine and Epidemiology
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
CT Medical Descriptors:
*chronic obstructive lung disease: DT, drug therapy
*chronic obstructive lung disease: EP, epidemiology
*chronic obstructive lung disease: ET, etiology
*chronic obstructive lung disease: SU, surgery
*chronic obstructive lung disease: TH, therapy
*lung transplantation
*pulmonary hypertension: DT, drug therapy
*pulmonary hypertension: ET, etiology
*lung embolism: DI, diagnosis
*lung embolism: ET, etiology
*pleura disease: DI, diagnosis

*pleura disease: ET, etiology
*pleura disease: SU, surgery
*air pollution
pathogenesis
genetic polymorphism
risk factor
alpha 1 antitrypsin deficiency: DT, drug therapy
alpha 1 antitrypsin deficiency: ET, etiology
mortality
oxygen therapy
smoking
pneumonia: ET, etiology
pathophysiology
breathing
breathing muscle
cardiovascular disease: SI, side effect
supraventricular tachycardia: SI, side effect
drug efficacy
drug megadose
corticosteroid therapy
corticosteroid induced osteoporosis: SI, side effect
vertebra fracture: SI, side effect
hip fracture: SI, side effect
proteinase inhibition
headache: SI, side effect
hyperlipidemia: SI, side effect
myalgia: SI, side effect
treatment outcome
asthma: DT, drug therapy
sickle cell anemia: ET, etiology
treatment indication
patient selection
bronchiolitis: ET, etiology
lung cancer: DI, diagnosis
lung cancer: EP, epidemiology
human
nonhuman
clinical trial
review
priority journal
Drug Descriptors:
technetium 99m
muscarinic receptor blocking agent: AE, adverse drug reaction
muscarinic receptor blocking agent: DT, drug therapy
ipratropium bromide: AE, adverse drug reaction
ipratropium bromide: DT, drug therapy
placebo
theophylline: CT, clinical trial
theophylline: DO, drug dose
theophylline: DT, drug therapy
theophylline: PD, pharmacology
glucocorticoid: AE, adverse drug reaction
glucocorticoid: CT, clinical trial
glucocorticoid: CM, drug comparison
glucocorticoid: DO, drug dose
glucocorticoid: DT, drug therapy
glucocorticoid: IH, inhalational drug administration

glucocorticoid: PO, oral drug administration
budesonide: AE, adverse drug reaction
budesonide: CT, clinical trial
budesonide: DT, drug therapy
budesonide: IH, inhalational drug administration
prednisolone: AE, adverse drug reaction
prednisolone: CT, clinical trial
prednisolone: DT, drug therapy
prednisolone: PO, oral drug administration
fluticasone propionate: CT, clinical trial
fluticasone propionate: CB, drug combination
fluticasone propionate: CM, drug comparison
fluticasone propionate: DO, drug dose
fluticasone propionate: DT, drug therapy
fluticasone propionate: IH, inhalational drug administration
salmeterol: CT, clinical trial
salmeterol: CB, drug combination
salmeterol: CM, drug comparison
salmeterol: DO, drug dose
salmeterol: DT, drug therapy
salmeterol: IH, inhalational drug administration
proteinase inhibitor: AE, adverse drug reaction
proteinase inhibitor: CT, clinical trial
proteinase inhibitor: CR, drug concentration
proteinase inhibitor: DT, drug therapy
proteinase inhibitor: PD, pharmacology
proteinase inhibitor: PO, oral drug administration
retinoic acid: AE, adverse drug reaction
retinoic acid: CT, clinical trial
retinoic acid: CR, drug concentration
retinoic acid: DT, drug therapy
retinoic acid: PD, pharmacology
ono 6818: PD, pharmacology
ono 6818: PO, oral drug administration
zd 0892: PD, pharmacology
alpha 1 antitrypsin: DT, drug therapy
ascorbic acid: DT, drug therapy
alpha tocopherol: DT, drug therapy
norfloxacin: PD, pharmacology
prostacyclin: DT, drug therapy
nitric oxide: DT, drug therapy
uniprost: CT, clinical trial
uniprost: DT, drug therapy
uniprost: SC, subcutaneous drug administration
monocrotaline: DT, drug therapy
monocrotaline: PD, pharmacology
simvastatin: DT, drug therapy
simvastatin: PD, pharmacology
3 hydroxy 3 methylglutaryl coenzyme A: DT, drug therapy
3 hydroxy 3 methylglutaryl coenzyme A: PD, pharmacology
sildenafil: DT, drug therapy
sildenafil: PD, pharmacology
phosphodiesterase inhibitor: DT, drug therapy
phosphodiesterase inhibitor: PD, pharmacology
D dimer: EC, endogenous compound
cyclosporin: PD, pharmacology
unclassified drug

RN (technetium 99m) 14133-76-7; (ipratropium bromide) 22254-24-6; (theophylline) 58-55-9, 5967-84-0, 8055-07-0, 8061-56-1, 99007-19-9; (budesonide) 51333-22-3; (prednisolone) 50-24-8; (fluticasone propionate) 80474-14-2; (salmeterol) 89365-50-4; (proteinase inhibitor) 37205-61-1; (retinoic acid) 302-79-4; (alpha 1 antitrypsin) 9041-92-3; (ascorbic acid) 134-03-2, 15421-15-5, 50-81-7; (alpha tocopherol) 1406-18-4, 1406-70-8, 52225-20-4, 58-95-7, 59-02-9; (norfloxacin) 70458-96-7; (prostacyclin) 35121-78-9, 61849-14-7; (nitric oxide) 10102-43-9; (uniprost) **81846-19-7**; (monocrotaline) 315-22-0, 8051-27-2; (simvastatin) 79902-63-9; (3 hydroxy 3 methylglutaryl coenzyme A) 1553-55-5; (sildenafil) 139755-83-2; (cyclosporin) 79217-60-0
CN Ono 6818; Zd 0892; Prolastin

L15 ANSWER 6 OF 8 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
ACCESSION NUMBER: 2003072829 EMBASE
TITLE: Gateways to clinical trials.
AUTHOR: Bayes M.; Rabasseda X.; Prous J.R.
CORPORATE SOURCE: M. Bayes, Prous Science, P.O. Box 540, 08080 Barcelona, Spain. mbayes@prous.com
SOURCE: Methods and Findings in Experimental and Clinical Pharmacology, (2002) 24/10 (703-729). after 1/16/02
Refs: 180
ISSN: 0379-0355 CODEN: MFEPDX
COUNTRY: Spain
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 018 Cardiovascular Diseases and Cardiovascular Surgery
037 Drug Literature Index
038 Adverse Reactions Titles
048 Gastroenterology
LANGUAGE: English
SUMMARY LANGUAGE: English
AB Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Studies knowledge area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: Abacavir sulfate, adalimumab, AERx morphine sulphate, alefacept, alemtuzumab, alendronic acid sodium salt, alicaforsen sodium, almotriptan, amprenavir, aripiprazole, atenolol, atorvastatin calcium; BSYX-A110; Cantuzumab mertansine, capravirine, CDP-571, CDP-870, celecoxib; Delavirdine mesilate, docetaxel, dofetilide, donepezil hydrochloride, duloxetine hydrochloride, dutasteride, dydrogesterone; Efavirenz, emtricitabine, enjuvia, enteryx, epristeride, erlotinib hydrochloride, escitalopram oxalate, etanercept, etonogestrel, etoricoxib; Fesoterodine, finasteride, flt3ligand; Galantamine hydrobromide, gemtuzumab ozogamicin, genistein, gepirone hydrochloride; Indinavir sulfate, infliximab; Lamivudine, lamivudine/zidovudine/abacavir sulfate, leteprinim potassium, levetiracetam, liposomal doxorubicin, lopinavir, lopinavir/ritonavir, losartan potassium; MCC-465, MRA; Nebivolol, nesiritide, nevirapine; Olanzapine, OROS(R)-Methylphenidate hydrochloride; Peginterferon alfa-2a, peginterferon alfa-2b, Pimecrolimus, polyethylene glycol 3350, pramlintide acetate, pregabalin, PRO-2000; Risedronate sodium, risperidone, ritonavir, rituximab, rivastigmine tartrate, rofecoxib, rosuvastatin calcium; Saquinavir mesilate, Stavudine; Tacrolimus, tadalafil, tamsulosin hydrochloride, telmisartan, tomoxetine hydrochloride, treprostinil sodium, trimegestone, trimetrexate; Valdecoxib, venlafaxine hydrochloride;

Zoledronic acid monohydrate. .COPYRGT. 2002 Prous Science. All rights reserved.

CT Medical Descriptors:
*drug research
medical literature
cardiovascular disease: DT, drug therapy
dose response
side effect: SI, side effect
gastrointestinal disease: DT, drug therapy
diarrhea: SI, side effect
virus infection: DT, drug therapy
metabolic disorder: DT, drug therapy
nutritional disorder: DT, drug therapy
musculoskeletal disease: DT, drug therapy
connective tissue disease
bone disease: DT, drug therapy
neoplasm: DT, drug therapy
neurologic disease: DT, drug therapy
mental disease: DT, drug therapy
kidney disease: DT, drug therapy
genital system disease: DT, drug therapy
thrombophlebitis: SI, side effect
breast disease: DT, drug therapy
skin disease: DT, drug therapy
human
clinical trial
meta analysis
review
Drug Descriptors:
nesiritide: CT, clinical trial
nesiritide: CB, drug combination
nesiritide: CM, drug comparison
nesiritide: DT, drug therapy
nesiritide: IV, intravenous drug administration
glyceryl trinitrate: CT, clinical trial
glyceryl trinitrate: CM, drug comparison
glyceryl trinitrate: DT, drug therapy
glyceryl trinitrate: IV, intravenous drug administration
milrinone: CT, clinical trial
milrinone: CB, drug combination
milrinone: DT, drug therapy
dofetilide: CT, clinical trial
dofetilide: DT, drug therapy
losartan: CT, clinical trial
losartan: DT, drug therapy
atenolol: CT, clinical trial
atenolol: DT, drug therapy
ascorbic acid: CT, clinical trial
ascorbic acid: CM, drug comparison
ascorbic acid: DT, drug therapy
ascorbic acid: PO, oral drug administration
atorvastatin: CT, clinical trial
atorvastatin: CM, drug comparison
atorvastatin: DT, drug therapy
atorvastatin: PO, oral drug administration
enalapril: CT, clinical trial
enalapril: CM, drug comparison

enalapril: DT, drug therapy
telmisartan: CT, clinical trial
telmisartan: CM, drug comparison
telmisartan: DT, drug therapy
nebivolol: CT, clinical trial
nebivolol: DT, drug therapy
uniprost: CT, clinical trial
uniprost: DO, drug dose
uniprost: DT, drug therapy
rosuvastatin: AE, adverse drug reaction
rosuvastatin: CT, clinical trial
rosuvastatin: DT, drug therapy
macrogol: AE, adverse drug reaction
macrogol: CT, clinical trial
macrogol: DO, drug dose
macrogol: DT, drug therapy
alicaforsen: CT, clinical trial
alicaforsen: DT, drug therapy
alicaforsen: IV, intravenous drug administration
tumor necrosis factor alpha antibody: AE, adverse drug reaction
tumor necrosis factor alpha antibody: CT, clinical trial
tumor necrosis factor alpha antibody: DT, drug therapy
tumor necrosis factor alpha antibody: IV, intravenous drug administration
etoricoxib: CT, clinical trial
etoricoxib: CM, drug comparison
etoricoxib: DT, drug therapy
etoricoxib: PO, oral drug administration
rofecoxib: CT, clinical trial
rofecoxib: CM, drug comparison
rofecoxib: DT, drug therapy
diclofenac: CT, clinical trial
diclofenac: CM, drug comparison
diclofenac: DT, drug therapy
infliximab: CT, clinical trial
infliximab: CB, drug combination
infliximab: DT, drug therapy
infliximab: IV, intravenous drug administration
prednisone: CT, clinical trial
prednisone: CB, drug combination
prednisone: DT, drug therapy
peginterferon alpha2a: CT, clinical trial
peginterferon alpha2a: CB, drug combination
peginterferon alpha2a: DT, drug therapy
peginterferon alpha2a: SC, subcutaneous drug administration
ribavirin: CT, clinical trial
ribavirin: CB, drug combination
ribavirin: IT, drug interaction
peginterferon alpha2b: CT, clinical trial
peginterferon alpha2b: CB, drug combination
peginterferon alpha2b: DT, drug therapy
lamivudine: CT, clinical trial
lamivudine: CB, drug combination
lamivudine: DT, drug therapy
lamivudine: PO, oral drug administration
abacavir: CT, clinical trial
abacavir: CB, drug combination

abacavir: DT, drug therapy
zidovudine: CT, clinical trial
zidovudine: CB, drug combination
zidovudine: DT, drug therapy
stavudine: CT, clinical trial
stavudine: CB, drug combination
stavudine: DT, drug therapy
delavirdine: CT, clinical trial
delavirdine: CB, drug combination
delavirdine: DT, drug therapy
unindexed drug

RN (nesiritide) 124584-08-3, 189032-40-4; (glyceryl trinitrate) 55-63-0; (milrinone) 78415-72-2; (dofetilide) 115256-11-6; (losartan) 114798-26-4; (atenolol) 29122-68-7; (ascorbic acid) 134-03-2, 15421-15-5, 50-81-7; (atorvastatin) 134523-00-5, 134523-03-8; (enalapril) 75847-73-3; (telmisartan) 144701-48-4; (nebivolol) 99200-09-6; (uniprost) **81846-19-7**; (rosuvastatin) 147098-18-8, 147098-20-2; (macrogol) 25322-68-3; (alicaforsen) 142442-63-5, 185229-68-9, 331257-52-4; (etoricoxib) 202409-33-4, 202409-40-3; (rofecoxib) 162011-90-7, 186912-82-3; (diclofenac) 15307-79-6, 15307-86-5; (infliximab) 170277-31-3; (prednisone) 53-03-2; (peginterferon alpha2a) 198153-51-4; (ribavirin) 36791-04-5; (peginterferon alpha2b) 215647-85-1; (lamivudine) 134678-17-4, 134680-32-3; (abacavir) 136470-78-5, 188062-50-2; (zidovudine) 30516-87-1; (stavudine) 3056-17-5; (delavirdine) 136817-59-9

CN Cdp 571

L15 ANSWER 7 OF 8 EMBASE
on STN

ACCESSION NUMBER: 2002412976 EMBASE
TITLE: News focus.
SOURCE: Current Drug Discovery, (1 Nov 2002) -/NOV. (11).
ISSN: 1472-7463 CODEN: CDDUAI
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; Note
FILE SEGMENT: 003 Endocrinology
004 Microbiology
016 Cancer
018 Cardiovascular Diseases and Cardiovascular Surgery
030 Pharmacology
037 Drug Literature Index
LANGUAGE: English

CT Medical Descriptors:
non insulin dependent diabetes mellitus: DT, drug therapy
glucose blood level
premature labor: DT, drug therapy
ovary insufficiency
fertilization in vitro
growth hormone deficiency: DT, drug therapy
solid tumor: DT, drug therapy
antineoplastic activity
aspergillosis: DT, drug therapy
bacterial infection: DT, drug therapy
drug potency
drug structure
antibacterial activity
pulmonary hypertension: DT, drug therapy
human

controlled study
note
Drug Descriptors:
*protein tyrosine phosphatase inhibitor: DT, drug therapy
*protein tyrosine phosphatase inhibitor: PD, pharmacology
*protein tyrosine phosphatase inhibitor: PO, oral drug administration
***antineoplastic agent: DT, drug therapy**
***antineoplastic agent: PD, pharmacology**
*antiinfective agent: AN, drug analysis
*antiinfective agent: CM, drug comparison
*antiinfective agent: DT, drug therapy
*antiinfective agent: PD, pharmacology
*antiinfective agent: IV, intravenous drug administration
as 602305: DT, drug therapy
as 602305: PO, oral drug administration
oxytocin antagonist: DT, drug therapy
oxytocin antagonist: PO, oral drug administration
recombinant follitropin: PD, pharmacology
sermorelin: DT, drug therapy
abt 100: DT, drug therapy
abt 100: PD, pharmacology
abt 839
protein farnesyltransferase inhibitor: DT, drug therapy
protein farnesyltransferase inhibitor: PD, pharmacology
abt 567: PD, pharmacology
angiogenesis inhibitor: PD, pharmacology
n [[5 [(2 amino 3 mercaptopropyl)amino][1,1' biphenyl] 2
yl]carbonyl]methionine
bms 379224: DT, drug therapy
bms 379224: IV, intravenous drug administration
antifungal agent: DT, drug therapy
antifungal agent: IV, intravenous drug administration
ravuconazole
chorismate synthase inhibitor: DT, drug therapy
chorismate synthase inhibitor: PD, pharmacology
phosphopantethiene adenyltransferase inhibitor: DT, drug therapy
phosphopantethiene adenyltransferase inhibitor: PD, pharmacology
ptx 110130: CM, drug comparison
ptx 110130: PD, pharmacology
ptx 008313: AN, drug analysis
ptx 008313: CM, drug comparison
ptx 008313: PD, pharmacology
a 00000764: AN, drug analysis
a 00000764: PD, pharmacology
a 00026158: PD, pharmacology
a 00000762: PD, pharmacology
ar 328: PD, pharmacology
antibiotic agent: AN, drug analysis
antibiotic agent: CM, drug comparison
antibiotic agent: DT, drug therapy
antibiotic agent: PD, pharmacology
uniprost: DT, drug therapy
uniprost: SC, subcutaneous drug administration
gepirone: PD, pharmacology
mirtazapine
antidepressant agent: PD, pharmacology
unindexed drug

unclassified drug
RN (sermorelin) 86168-78-7; (n [[5 [(2 amino 3 mercaptopropyl)amino][1,1' biphenyl] 2 yl]carbonyl]methionine) 170006-72-1; (ravuconazole) 182760-06-1; (uniprost) **81846-19-7**; (gepirone) 83928-66-9, 83928-76-1; (mirtazapine) 61337-67-5
CN (1) As 602305; (2) Abt 100; (3) Abt 567; (4) Abt 839; (5) Fti 276; (6) Bms 379224; (7) Ptx 110130; (8) Ptx 008313; (9) A 00000764; (10) A 00000762; (11) A 00026158; (12) Ar 328; (13) Ariza; (14) Remeron
CO (1) Serono; (4) Abbott; (5) University of Pittsburgh; (6) Bristol Myers Squibb; (8) PanTherix; (11) Arrow; (12) Arpida; (14) Organon

L15 ANSWER 8 OF 8 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
ACCESSION NUMBER: 2002123171 EMBASE
TITLE: News focus.
SOURCE: Current Drug Discovery, (2002) -/MAR. (15-18).
ISSN: 1472-7463 CODEN: CDDUAI
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 016 Cancer
017 Public Health, Social Medicine and Epidemiology
030 Pharmacology
037 Drug Literature Index
039 Pharmacy
LANGUAGE: English
CT Medical Descriptors:
multidrug resistance
degenerative disease: DT, drug therapy
diabetes mellitus: DT, drug therapy
graft versus host reaction: DT, drug therapy
bacterial infection: DT, drug therapy
Human immunodeficiency virus infection: DT, drug therapy
basal cell carcinoma: DT, drug therapy
actinic keratosis: DT, drug therapy
pulmonary hypertension: DT, drug therapy
melanoma: DT, drug therapy
cystic fibrosis: DT, drug therapy
colorectal cancer: DT, drug therapy
heart failure: DT, drug therapy
obesity: DT, drug therapy
erectile dysfunction: DT, drug therapy
female sexual dysfunction: DT, drug therapy
hip fracture: DT, drug therapy
human
nonhuman
clinical trial
controlled study
article
Drug Descriptors:
*new drug: CT, clinical trial
*new drug: AN, drug analysis
*new drug: DT, drug therapy
*new drug: PR, pharmaceutics
*new drug: PD, pharmacology
*new drug: NA, intranasal drug administration
*new drug: PO, oral drug administration
protein inhibitor: CT, clinical trial

protein inhibitor: DT, drug therapy
ont 093: CT, clinical trial
ont 093: DT, drug therapy
glutamate receptor antagonist: DV, drug development
glutamate receptor antagonist: DT, drug therapy
ro 68 0921: DV, drug development
ro 68 0921: DT, drug therapy
ro 64 5229: DV, drug development
ro 64 5229: DT, drug therapy
metalloproteinase inhibitor: DV, drug development
metalloproteinase inhibitor: DT, drug therapy
kb r7785: DV, drug development
kb r7785: DT, drug therapy
antiinfective agent: AN, drug analysis
antiinfective agent: DV, drug development
antiinfective agent: PD, pharmacology
pyrrole derivative: AN, drug analysis
pyrrole derivative: DV, drug development
pyrrole derivative: PD, pharmacology
tenofovir disoproxil: DT, drug therapy
antineoplastic agent: DT, drug therapy
antineoplastic agent: PR, pharmaceutics
metvix pdt: DT, drug therapy
metvix pdt: PR, pharmaceutics
uniprost: CT, clinical trial
uniprost: DT, drug therapy
doxycycline: PO, oral drug administration
bacterial vaccine: DT, drug therapy
aerugen: DT, drug therapy
cancer vaccine: CT, clinical trial
cancer vaccine: DT, drug therapy
oncophage: DT, drug therapy
theratope: CT, clinical trial
theratope: DT, drug therapy
angiogenesis inhibitor: CT, clinical trial
angiogenesis inhibitor: DT, drug therapy
semaxinib: CT, clinical trial
semaxinib: DT, drug therapy
endothelin receptor antagonist: CT, clinical trial
endothelin receptor antagonist: DT, drug therapy
bosentan: CT, clinical trial
bosentan: DT, drug therapy
antiobesity agent: CT, clinical trial
antiobesity agent: DT, drug therapy
aod 9604: CT, clinical trial
aod 9604: DT, drug therapy
apomorphine: DT, drug therapy
apomorphine: NA, intranasal drug administration
growth hormone releasing factor: DT, drug therapy
th 9507: DT, drug therapy
unindexed drug
unclassified drug
pennsaid
viread

RN (tenofovir disoproxil) 202138-50-9; (uniprost) **81846-19-7;** (doxycycline) 10592-13-9, 17086-28-1, 564-25-0; (apomorphine) 314-19-2, 58-00-4; (growth hormone releasing factor) 83930-13-6, 9034-39-3

CN (1) Ont 093; (2) Ro 68 0921; (3) Ro 64 5229; (4) Kb r7785; (5) Metvix pdt; (6) Remodulin; (7) Oncophage; (8) Periostat; (9) Pennsaid; (10) Aerugen; (11) Theratope; (12) Semaxinib; (13) Tracleer; Viread

CO (1) Ontogen; (3) Hoffmann La Roche; (4) Organon; (5) PhotoCure; (6) United Therapeutics; (7) Antigenics; (8) Collagenex; (9) Dimethaid; (10) Berna; (11) Biomira; (12) Pharmacia; (13) Genentech; Genelabs; Nastech